Sun, Sep 21, 2014, 10:48 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. (SNTA) Message Board

  • richrd_cc richrd_cc Aug 20, 2014 10:07 AM Flag

    Ganetespib Study Timeline - may not be complete

    An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer (Enchant) Estimated Completion Date Dec-14
    Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
    Estimated Completion Date Feb-15
    Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers
    Estimated Completion Date A pr-15
    A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma
    Estimated Completion Date Sep-15
    Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer
    Estimated Completion Date Nov-15
    Ganetespib With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma (MESO-02)
    Estimated Completion Date Dec-15
    A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC (Galaxy 2) Estimated Completion Date Mar-16
    Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Estimated Completion Date Sep-16
    Ganetespib, Paclitaxel and Trastuzumab for Advanced or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer Estimated Completion Date Sep-16
    (continued)

    Sentiment: Strong Buy

 
SNTA
3.55-0.17(-4.57%)Sep 19 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.